Nontoxic suramin as a chemosensitizer in patients: Dosing nomogram development

Pharmaceutical Research

Volumn 23, Issue 6, 2006, Pages 1265-1274

  Chen, Danny ^a   Song, Sae Heum ^a   Wientjes, M Guillaume ^a,b   Yeh, Teng Kuang ^a   Zhao, Liang ^a   Villalona Calero, Miguel ^a,b   Otterson, Gregory A ^a,b   Jensen, Rhonda ^a,b   Grever, Michael ^a,b   Murgo, Anthony J ^c   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemosensitization; Dosing nomogram; Neoplasms; Suramin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CREATININE; PACLITAXEL; SERUM ALBUMIN; SURAMIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHEMOSENSITIZATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DOSING NOMOGRAM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIZATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INDIVIDUALIZATION; INTERSUBJECT VARIABILITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MAXIMUM TOLERATED DOSE; NOMOGRAM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MODELS, BIOLOGICAL; NOMOGRAMS; PACLITAXEL; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; SURAMIN;

EID: 33745354410     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-0165-1     Document Type: Article

References (43)

1. S. Song M. G. Wientjes Y. Gan J. L. Au 2000 Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs Proc. Natl. Acad. Sci. USA 97 8658 8663
2. S. Song M. G. Wientjes C. Walsh J. L. Au 2001 Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases Cancer Res. 61 6145 6150
3. Y. Zhang S. Song F. Yang J. L. Au M. G. Wientjes 2001 Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors J. Pharmacol. Exp. Ther. 299 426 433
4. C. E. Hensey D. Boscoboinik A. Azzi 1989 Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A FEBS Lett. 258 156 158
5. T. P. Wade A. Kasid C. A. Stein R. V. LaRocca E. R. Sargent L. G. Gomella C. E. Myers W. M. Linehan 1992 Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture J. Surg. Res. 53 195 198
6. E. De Clercq 1979 Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses Cancer Lett. 8 9 22
7. H. Nakane J. Balzarini E. De Clercq K. Ono 1988 Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acid Eur. J. Biochem. 177 91 96
8. S. T. Palayoor E. A. Bump B. A. Teicher C. N. Coleman 1997 Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin Radiat. Res. 148 105 114
9. L. Qiao J. G. Pizzolo M. R. Melamed 1994 Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 carcinoma cells Biochem. Biophys. Res. Commun. 201 581 588
10. W. K. Evans C. C. Earle D. J. Stewart S. Dahrouge E. Tomiak G. Goss D. Logan R. Goel S. Z. Gertler H. Dulude 1997 Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer Lung Cancer 18 83 94
11. J. H. Kim E. R. Sherwood D. M. Sutkowski C. Lee J. M. Kozlowski 1991 Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution J. Urol. 146 171 176
12. F. Hawking 1978 Suramin: with special reference to onchocerciasis Adv. Pharmacol. Chemother. 15 289 322
13. S. M. Tu L. C. Pagliaro M. E. Banks R. J. Amato R. E. Millikan N. A. Bugazia T. Madden R. A. Newman C. J. Logothetis 1998 Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer Clin. Cancer Res. 4 1193 1201
14. M. R. Cooper R. Lieberman R. V. La Rocca P. R. Gernt M. S. Weinberger D. J. Headlee D. R. Kohler B. R. Goldspiel C. C. Peck C. E. Myers 1992 Adaptive control with feedback strategies for suramin dosing Clin. Pharmacol. Ther. 52 11 23
15. M. A. Eisenberger V. J. Sinibaldi L. M. Reyno R. Sridhara D. I. Jodrell E. G. Zuhowski K. H. Tkaczuk M. H. Lowitt R. K. Hemady S. C. Jacobs 1995 Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer J. Clin. Oncol. 13 2174 2186
16. L. M. Reyno M. J. Egorin M. A. Eisenberger V. J. Sinibaldi E. G. Zuhowski R. Sridhara 1995 Development and validation of a pharmacokinetically based fixed dosing scheme for suramin J. Clin. Oncol. 14 2187 2195
17. K. Kobayashi E. E. Vokes N. J. Vogelzang L. Janisch B. Soliven M. J. Ratain 1996 Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose J. Clin. Oncol. 14 2622 2623
18. S. Song B. Yu Y. Wei M. G. Wientjes J. L. Au 2004 Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors Clin. Cancer Res. 10 6058 6065
19. Y. Xin G. Lyness D. Chen S. Song M. G. Wientjes J. L. Au 2005 Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C J. Urol. 174 322 327
20. B. Yu S.-H. Song M. G. Wientjes J. L. Au 2003 Suramin enhances activity of CPT-11 in human colorectal xenograft tumors Proc. Am. Assoc. Cancer Res. 44 174
21. A. Falcone E. Pfanner I. Brunetti G. Allegrini M. Lencioni C. Galli G. Masi R. Danesi A. Antonuzzo M. Del Tacca P. F. Conte 1998 Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+ LV-based chemotherapy Tumori 84 666 668
22. A. Falcone A. Antonuzzo R. Danesi G. Allegrini L. Monica E. Pfanner G. Masi S. Ricci M. Del Tacca P. F. Conte 1999 Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma Cancer 86 470 476
23. B. L. Rapoport G. Falkson J. I. Raats M. de Wet B. P. Lotz H. C. Potgieter 1993 Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study Ann. Oncol. 4 567 573
24. M. A. Villalona-Calero M. G. Wientjes G. A. Otterson S. Kanter D. Young A. J. Murgo B. Fischer C. DeHoff D. Chen T. K. Yeh S. Song M. Grever J. L. Au 2003 Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer Clin. Cancer Res. 9 3303 3311
25. M. Kassack P. Nickel 1996 Rapid, highly sensitive gradient narrow-bore high-performance liquid chromatographic determination of suramin and its analogues J. Chromatogr. B Biomed. Appl. 686 275 284
26. D. M. Ornitz N. Itoh 2001 Fibroblast growth factors Genome Biol. 2 3005
27. P. Tothill L. Matheson J. Smyth K. [tmp] McKay 1990 Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry J. Anal. At. Spectrom. 5 619 622
28. L. B. Sheiner B. Rosenberg V. V. Marathe 1977 Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J. Pharmacokinet. Biopharm. 5 445 479
29. J. W. Mandema D. Verotta L. B. Sheiner 1992 Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J. Pharmacokinet. Biopharm. 20 511 528
30. W. D. Gabrielsson J. Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications. Swedish Pharmaceutical Press, 1994.
31. A. H. Calvert D. R. Newell L. A. Gumbrell S. O'Reilly M. Burnell F. E. Boxall Z. H. Siddik I. R. Judson M. E. Gore E. Wiltshaw 1989 Carboplatin dosage: prospective evaluation of a simple formula based on renal function J. Clin. Oncol. 7 1748 1756
32. M. T. Huizing A. C. Keung H. Rosing V. van der Kuij W. W. Bokkel Huinink I. M. Mandjes A. C. Dubbelman H. M. Pinedo J. H. Beijnen 1993 Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients J. Clin. Oncol. 11 2127 2135
33. M. T. Huizing L. J. van Warmerdam H. Rosing M. C. Schaefers A. Lai T. J. Helmerhorst C. H. Veenhof M. J. Birkhofer S. Rodenhuis J. H. Beijnen W. W. Bokkel Huinink 1997 Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer J. Clin. Oncol. 15 1953 1964
34. N. Siddiqui A. V. Boddy H. D. Thomas N. P. Bailey L. Robson M. J. Lind A. H. Calvert 1997 A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer Br. J. Cancer 75 287 294
35. P. R. Hoban M. I. Walton C. N. Robson J. Godden I. J. Stratford P. Workman A. L. Harris I. D. Hickson 1990 Decreased NADPH: cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions Cancer Res. 50 4692 4697
36. H. F. Bligh A. Bartoszek C. N. Robson I. D. Hickson C. B. Kasper J. D. Beggs C. R. Wolf 1990 Activation of mitomycin C by NADPH:cytochrome P-450 reductase Cancer Res. 50 7789 7792
37. R. D. Traver D. Siegel H. D. Beall R. M. Phillips N. W. Gibson W. A. Franklin D. Ross 1997 Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase) Br. J. Cancer 75 69 75
38. D. I. Jodrell L. M. Reyno R. Sridhara M. A. Eisenberger K. H. Tkaczuk E. G. Zuhowski V. J. Sinibaldi M. J. Novak M. J. Egorin 1994 Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer J. Clin. Oncol. 12 166 175
39. P. R. Hutson K. D. Tutsch G. Wilding 1995 Pharmacokinetic analysis and adaptive control of suramin D. Z. D'Argenio Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, Volume 2 Plenum Press New York 177 187
40. J. M. Collins R. W. Klecker Jr. R. Yarchoan H. C. Lane A. S. Fauci R. R. Redfield S. Broder C. E. Myers 1986 Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection J. Clin. Pharmacol. 26 22 26
41. S. C. Piscitelli A. Forrest R. M. Lush N. Ryan L. R. Whitfield D. Figg 1997 Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics Pharmacotherapy 17 431 437
42. P. R. Hutson K. D. Tutsch R. Rago R. Arzoomanian D. Alberti M. Pomplun D. Church R. Marnocha A. L. Cheng N. Kehrli G. Wilding 1998 Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin Clin. Cancer Res. 4 1429 1436
43. 14C]suramin in tissues of male rats following a single intravenous dose Life Sci. 67 1847 1857